T‐cell‐depleted allogeneic bone marrow transplantation for acute leukaemia using Campath‐1 antibodies and post‐transplant administration of donor's peripheral blood lymphocytes for prevention of relapse

One hundred and forty‐six patients with acute leukaemia (81 with ANLL and 65 with ALL) received allogeneic bone marrow transplantation from their fully matched siblings. 121 patients underwent T‐cell depletion (TCD) using Campath 1 monoclonal rat anti‐human lymphocyte (CDw52) antibodies; 67 with Campath 1M and 54 with Campath 1G isotypes. Patients were conditioned for transplant using either total body irradiation combined with chemotherapy (125 patients) or busulfan and cyclophosphamide (21 patients). 112 recipients of T‐cell depleted allografts received in addition total lymphoid irradiation (TLI) for prevention of rejection. Engraftment of neutrophils (>0.5 × 109/l) and platelets (>25 × 109/l) occurred on days 15 and 18, and on days 18 and 20 in recipients of Campath 1M and Campath 1G treated marrows respectively. Rejection was documented in 6.8% of T‐cell depleted transplants. Leukaemia relapse‐free survival at 2 years was 83% for patients transplanted in first CR, 76% in second CR (P2= 0.34) and 42% in advanced leukaemia (P2= 0.009). 81 marrow recipients, 38 with Campath 1M and 43 with Campath 1G treated marrow, received post‐transplant graded increments of donor's peripheral blood lymphocytes (PBL) to induce graft‐versus‐leukaemia (GVL) effects. Administration of donor's PBL was associated with clinically significant GVHD and with decreased relapse rate especially in patients with ALL. Our data suggest that in patients receiving marrow allografts depleted of T cells by Campath 1 monoclonal antibodies, rejection can be reduced by adequate pregrafting immunosuppression. In patients with advanced disease, post‐transplant cell‐mediated immunotherapy (CMI) using donor's PBL may be beneficial; however, further studies are needed to define the optimal schedule of CMI for safe and effective prevention of relapse following TCD bone marrow transplantation in malignant haematological diseases.

[1]  D. Porter,et al.  Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. , 1994, The New England journal of medicine.

[2]  S. Thibodeau,et al.  Molecular remission occurring after donor leukocyte infusions for the treatment of relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. , 1992, Bone marrow transplantation.

[3]  S. Slavin,et al.  Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders: I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL-2-activated cell-mediated , 1992, Cancer investigation.

[4]  A. Nagler,et al.  Immunotherapy of minimal residual disease by immunocompetent lymphocytes and their activation by cytokines. , 1992, Cancer investigation.

[5]  R. Macklis,et al.  Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. , 1991, Blood.

[6]  R. Truitt,et al.  Impact of pretransplant conditioning and donor T cells on chimerism, graft-versus-host disease, graft-versus-leukemia reactivity, and tolerance after bone marrow transplantation. , 1991, Blood.

[7]  S. Mackinnon,et al.  Induction of in vitro graft-versus-leukemia activity following bone marrow transplantation for chronic myeloid leukemia. , 1990, Blood.

[8]  S. Slavin,et al.  The graft-versus-leukemia (GVL) phenomenon: is GVL separable from GVHD? , 1990, Bone marrow transplantation.

[9]  Deeg Hj,et al.  Management of acute graft-versus-host disease. , 1990, Bone marrow transplantation.

[10]  A. Rimm,et al.  Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. , 1990, Blood.

[11]  G. D. de Gast,et al.  A fixed low number of T cells in HLA-identical allogeneic bone marrow transplantation. , 1990, Blood.

[12]  A. Rimm,et al.  Graft-versus-leukemia reactions after bone marrow transplantation. , 1990, Blood.

[13]  B. Shank,et al.  Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia: I. Analysis of risk factors and results of secondary transplants , 1989 .

[14]  C. Bordignon,et al.  Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia: II. In vitro analyses of host effector mechanisms. , 1989, Blood.

[15]  H. Waldmann,et al.  T cell depletion of human bone marrow. Comparison of Campath-1 plus complement, anti-T cell ricin A chain immunotoxin, and soybean agglutinin alone or in combination with sheep erythrocytes or immunomagnetic beads. , 1989, Transplantation.

[16]  R Storb,et al.  Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. , 1989, Blood.

[17]  H. Deeg,et al.  Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. , 1989, Blood.

[18]  A. Gee,et al.  T‐CELL DEPLETION OF HUMAN BONE MARROW , 1989, Journal of immunogenetics.

[19]  K. Sullivan,et al.  Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. , 1989, The New England journal of medicine.

[20]  K. Sullivan,et al.  Deletion of immunosuppressive prophylaxis after marrow transplantation increases hyperacute graft-versus-host disease but does not influence chronic graft-versus-host disease or relapse in patients with advanced leukemia , 1989 .

[21]  R. Hoffmann,et al.  Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. , 1988 .

[22]  G. Hale,et al.  T CELL DEPLETION WITH CAMPATH‐1 IN ALLOGENEIC BONE MARROW TRANSPLANTATION , 1988, Transplantation.

[23]  R. Storb,et al.  Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials , 1988 .

[24]  R. Storb,et al.  Second marrow transplants in patients with leukemia who relapse after allogeneic marrow transplantation. , 1988, Bone marrow transplantation.

[25]  R. Hoffmann,et al.  Risk factors for acute graft‐versus‐host disease , 1987, British journal of haematology.

[26]  J. Sprent,et al.  T cell subsets and graft-versus-host disease. , 1987, Transplantation.

[27]  H. Waldmann,et al.  The Depletion of T Cell Subsets in Vitro and in Vivo , 1986 .

[28]  R. Gale,et al.  GRAFT REJECTION AND GRAFT-VERSUS-HOST DISEASE: MIRROR IMAGES , 1986, The Lancet.

[29]  J. Gribben,et al.  Graft rejection following HLA matched T‐lymphocyte depleted bone marrow transplantation , 1986, British journal of haematology.

[30]  H. Deeg,et al.  Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. , 1986, The New England journal of medicine.

[31]  D. Engelhard,et al.  New approaches for the prevention of rejection and graft-vs.-host disease in clinical bone marrow transplantation. , 1986, Israel journal of medical sciences.

[32]  H. Waldmann,et al.  Monoclonal antibodies for the prevention of graft-versus-host disease and marrow graft rejection. The depletion of T cell subsets in vitro and in vivo. , 1986, Transplantation.

[33]  K. Sullivan.  Acute and chronic graft-versus-host disease in man. , 1986, International journal of cell cloning.

[34]  H. Deeg,et al.  Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts , 1985 .

[35]  J. Michaeli,et al.  PREVENTION OF GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR LEUKEMIA BY T-CELL DEPLETION INVITRO PRIOR TO TRANSPLANTATION , 1985 .

[36]  H. Deeg,et al.  Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. , 1985, Blood.

[37]  G. Hale,et al.  ELIMINATION OF GRAFT-VERSUS-HOST DISEASE BY IN-VITRO DEPLETION OF ALLOREACTIVE LYMPHOCYTES WITH A MONOCLONAL RAT ANTI-HUMAN LYMPHOCYTE ANTIBODY (CAMPATH-1) , 1984, The Lancet.

[38]  R. Nuscher,et al.  Bone marrow transplantation. , 1977, The American journal of nursing.

[39]  T. Hoang,et al.  Removal of T cells from bone marrow for transplantation. Comparison of rat monoclonal anti-lymphocyte antibodies of different isotypes. , 1983, Molecular biology & medicine.

[40]  G. Hale,et al.  Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. , 1983, Blood.

[41]  K. Sullivan,et al.  Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. , 1981, The New England journal of medicine.

[42]  R. Storb,et al.  Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. , 1979, The New England journal of medicine.

[43]  Z. Fuks,et al.  Transplantation of allogeneic bone marrow without graft-versus-host disease using total lymphoid irradiation , 1978, The Journal of experimental medicine.

[44]  D. Cox.  Regression Models and Life-Tables , 1972 .

[45]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[46]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[47]  D.,et al.  Regression Models and Life-Tables , 2022 .